Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes

• Váldodahkkit: Dan Zheng (Dahkki), Xiaolin Hou (Dahkki), Jing Yu (Dahkki), Xiujing He (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

As an emerging antitumor strategy, immune checkpoint therapy is one of the most promising anticancer therapies due to its long response duration. Antibodies against the programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) axis have been extensively applied to various cancers and have demo...